Funded Tech Companies

OncoMyx Therapeutics

Researching who provided funding to OncoMyx Therapeutics? Boehringer Ingelheim Venture Fund, Delos Capital and LYZZ Capital put venture money into this biopharmaceutical company.

Company Overview

Contact Information

Company Background Information

Overview

OncoMyx Therapeutics is developing oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have emerged as a safe and effective IO complement.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

12/9/2021

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Steve Potts

        

Chief Operating Officer

Michael Wood

        

Chief Scientific Officer

Leslie Sharp

        

VP - R & D

Grant McFadden

        

Company Investors

• Boehringer Ingelheim Venture Fund
• Delos Capital
• LYZZ Capital
• B Capital Group
• Xeraya Capital
• Lumira Capital
• Korea Investment Partners
• Madison Partners
• City Hill Ventures

Browse more funded tech companies:

OncoMed Pharmaceuticals | OncoNano Medicine

Share this article

About Our Venture Capital Database

This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary